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Abstract 
Neutropenia is defined by either an absolute or functional defect (acute myeloid leukemia or myelodysplastic syn‑
drome) of polymorphonuclear neutrophils and is associated with high risk of specific complications that may require 
intensive care unit (ICU) admission. Specificities in the management of critically ill neutropenic patients prompted the 
establishment of guidelines dedicated to intensivists. These recommendations were drawn up by a panel of experts 
brought together by the French Intensive Care Society in collaboration with the French Group for Pediatric Intensive 
Care Emergencies, the French Society of Anesthesia and Intensive Care, the French Society of Hematology, the French 
Society for Hospital Hygiene, and the French Infectious Diseases Society. Literature review and formulation of recom‑
mendations were performed using the Grading of Recommendations Assessment, Development and Evaluation 
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Background
Neutropenia is defined by an absolute count of polymor-
phonuclear neutrophils (PMNs) less than 1500/mm3 [1]. 
Infections are the main complication of this condition, 
and the risk is higher when neutropenia is profound 
(PMN < 500/mm3) and/or prolonged (more than 7 days) 
[2, 3]. The diagnosis of these infections is hampered by 
the relative paucity of symptoms, leading to severe sta-
tus in cases of delayed diagnosis [2, 4]. In intensive care 
unit (ICU), up to 2.4 % of the overall population [5], 8.6 % 
of patients with sepsis or septic shock [6], and 28.6 % of 
hematological patients [7] will experience neutropenia or 
leucopenia during their ICU stay.
Management strategies for neutropenic patients in the 
ICU often rely on low-grade evidence derived from an 
extensive but sometimes contradictory medical litera-
ture partly ascribable to small single-center observational 
cohort studies, variability regarding centers experience 
and volume of critically ill cancer patients, and rela-
tively old studies. The management specificities of these 
patients in the ICU prompted the establishment of guide-
lines dedicated to intensivists.
Methods
These recommendations were drawn up by a panel of 
experts brought together by the French Intensive Care 
Society (SRLF) in collaboration with scientific societies 
in disciplines that contribute to the management of neu-
tropenic patients: the French Group for Pediatric Inten-
sive Care Emergencies (GFRUP), the French Society of 
Anesthesia and Intensive Care (SFAR), the French Soci-
ety of Hematology (SFH), the French Society for Hospi-
tal Hygiene (SF2H), and the French Infectious Diseases 
Society (SPILF). The organizing committee appointed a 
coordinator, who selected the SRLF experts. Each asso-
ciated scientific society selected its experts. The coordi-
nator first defined the field to be covered and proposed 
experts to be in charge of each fields. Fields were then 
refined and validated by experts. Literature analysis and 
formulation of recommendations were then performed 
using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system [8, 9]. 
A level of evidence was defined for each bibliographic 
reference as a function of the type of study. This level of 
evidence could be reassessed by considering the meth-
odological quality of the study. The bibliographic refer-
ences common to each outcome were then pooled. An 
overall level of evidence was determined for each out-
come, considering the level of evidence of each biblio-
graphic reference, the consistency of the results between 
the different studies, the direct or indirect nature of the 
evidences, cost analysis, and so forth. A “strong” level 
(Grade 1+ or 1−) of evidence enabled the formulation 
of a “strong” recommendation (i.e., should be done, 
should not be done) (Table 1). A “moderate,” “weak,” or 
“very weak” level of evidence (Grade 2+ or 2−) led to 
the drawing up of an “optional” recommendation (i.e., 
should probably be done, should probably not be done). 
When the evidence was lacking, a recommendation 
resulting from “expert opinion” could be formulated. 
The proposed recommendations were then presented 
to and discussed with the whole panel of experts. The 
aim was not necessarily to reach a single and conver-
gent opinion of the experts regarding all proposals but 
to bring out the points of agreement and disagreement 
or of indecision. Each recommendation was then evalu-
ated and rated by each expert according to a scale from 
1 (complete disagreement) to 9 (complete agreement). 
The collective score was established using a methodol-
ogy derived from the RAND/UCLA Appropriateness 
Method [10]. After elimination of the extreme values 
(outliers), the median and terminals of the scores were 
calculated. The median defined disagreement between 
the experts when it was between 1 and 3, agreement 
between 7 and 9, and indecision between 4 and 6. The 
disagreement, agreement, or indecision was “strong” if 
the terminals were within the same range and “weak” 
if the terminals straddled two ranges. In the absence of 
strong agreement, the recommendations were reformu-
lated and again scored with a view to achieving a bet-
ter consensus. Two rounds of scoring were therefore 
performed.
system. Each recommendation was then evaluated and rated by each expert using a methodology derived from the 
RAND/UCLA Appropriateness Method. Six fields are covered by the provided recommendations: (1) ICU admission 
and prognosis, (2) protective isolation and prophylaxis, (3) management of acute respiratory failure, (4) organ failure 
and organ support, (5) antibiotic management and source control, and (6) hematological management. Most of the 
provided recommendations are obtained from low levels of evidence, however, suggesting a need for additional 
studies. Seven recommendations were, however, associated with high level of evidences and are related to protective 
isolation, diagnostic workup of acute respiratory failure, medical management, and timing surgery in patients with 
typhlitis.
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A panel of pediatricians reviewed the pediatric lit-
erature. In the absence of available evidence or pediatric 
specificity, adult recommendations apply to the pediatric 
patients. In case of pediatric specificity, a dedicated rec-
ommendation was planned to be added, supported by 
an argumentative text and with specific validation by the 
pediatrician panel.
Results and recommendations
Scope of the recommendations
The present recommendations apply to neutropenia of all 
etiologies, except for constitutive, hereditary, newborn 
autoimmune-related neutropenia, and transient sepsis-
induced neutropenia. Considering a higher infectious risk 
during profound neutropenia (PMN less than 500/mm3), 
they apply particularly to these patients. They also apply 
to patients with non-functional PMN (functional neutro-
penia) and neutropenia expected in the coming 48 h.
Six fields were predefined:
I.  ICU admission and prognosis
II.  Protective isolation and prophylaxis
III.  Acute respiratory failure (ARF)
IV.  Organ failure and support
V.  Antibiotic management and source control (except 
for invasive fungal infection)
VI.  Hematological management (hematopoietic growth 
factors and transfusions, except for platelet transfu-
sions evaluated in previous recommendations) [11].
The experts in charge of the fifth field considered, as 
regards to the lack of specific data in ICU patients regard-
ing antifungal management, either for empirical or for 
curative treatment that this point was outside the scope 
of the current recommendations. The experts agreed that 
usual recommendations (http://www.kobe.fr/ecil/pub-
lications.htm) should apply to critically ill neutropenic 
patients. In the same line, since specific recommenda-
tions exist regarding management of febrile neutropenia 
[2], only specificities of critically ill neutropenic patients 
were reported in this statement.
Seventeen experts and one coordinator participated 
as per these recommendations. A bibliographic review, 
including publications in French and English, was done 
in the PubMed and Cochrane databases. A specific analy-
sis of the pediatric literature was also performed.
Forty recommendations were formulated, including 
a specific pediatric recommendation (Table  2). Among 
them, 7 were strong recommendations, 28 were weak 
recommendations, and 5 resulted from expert opinion. 
Twenty-six (65  %) recommendations obtained a strong 
agreement.
ICU admission and prognosis
RI‑1 Neutropenia should probably not be used as tri-
age criteria in cancer patients considered for ICU admis-
sion. Performance status, comorbidities, and potentially 
life-prolonging treatment available are more relevant in 
this regard (Grade 2−, strong agreement).
RI‑2 Neutropenia should probably not be considered as 
a prognostic factor in critically ill cancer patients (Grade 
2−, weak agreement).
RI‑3 Intensive care unit admission should probably not 
be delayed if ICU admission is deemed necessary in criti-
cally ill cancer patients (Grade 2−, strong agreement).
The prognostic impact of neutropenia remains con-
troversial. Hence, neutropenia remains a transient and 
expected immune dysfunction. Although neutropenia is 
an independent risk factor for poor outcome in the gen-
eral ICU population with severe sepsis or septic shock 
[6] and in earlier cohorts of critically ill cancer patients 
[12, 13], several recent studies failed to demonstrate any 
impact of neutropenia, neutropenia duration, or resolu-
tion of neutropenia on the outcome of critically ill can-
cer patients [7, 14–24]. Although this finding remains 
in an unselected population of neutropenic critically ill 
patients, it must be noted that specific infectious disease 
such as Fusarium infection is associated with a nearly 
Table 1 Evidence grading and recommendations formulation
Risk of bias and grade Type of recommendation Formulation
Low: Grade 1 Positive recommendation + Should be
High level of evidence Negative recommendation − Should not be
Intermediate to high: Grade 2 Positive recommendation + Should probably be
Intermediate to low level of evidence Negative recommendation − Should probably not be
High: expert opinion Positive recommendation + Should probably be (expert opinion)
No available data Negative recommendation − Should probably not be (expert opinion)
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Table 2 Summary of expert recommendations
I. ICU admission and prognosis
RI‑1—Neutropenia should probably not be used as triage criteria in cancer patients considered for ICU admission. Performance status, comorbidities, 
and potentially life‑prolonging treatment available are more relevant in this regard (Grade 2−, strong agreement)
RI‑2—Neutropenia should probably not be considered as a prognostic factor in critically ill cancer patients (Grade 2‑, weak agreement)
RI‑3−Intensive care unit admission should probably not be delayed if ICU admission is deemed necessary in critically ill cancer patients (Grade 2‑, 
strong agreement)
II. Prophylaxis and protective isolation
RII‑1—Protective isolation should probably be considered in patients with profound (neutrophil count less than 500/mm3) and prolonged (expected 
neutropenia duration more than 7 days) neutropenia (Grade 2+, strong agreement)
RII‑2—Protective isolation should not be considered as a sterile isolation (Grade 1‑, strong agreement)
RII‑3—Protective isolation should not delay ICU admission or limit patients’ clinical monitoring or access to patients’ rooms in cases of emergency 
(Grade 1‑, strong agreement).
RII‑4—Antibacterial prophylaxis should probably not be performed in critically patients with neutropenia (Grade 2‑, strong agreement)
RII‑5—Anti‑Aspergillus prophylaxis should probably be used in critically ill neutropenic patients with acute myeloid leukemia or myelodysplastic syn‑
drome with both induction and consolidation therapy used when neutropenia is expected to be profound (neutrophil count less than 500/mm3) and 
with an expected duration of at least 15 days (Grade 2+, weak agreement)
RII‑6—Anti‑Aspergillus prophylaxis should probably be used in high‑risk critically ill neutropenic patients (myeloablative conditioning regimens, older 
patients, transplant in patients with active disease, umbilical/placental cord blood transplant) (Grade 2+, weak agreement)
RII‑7−Anti‑Aspergillus prophylaxis should probably be used in critically ill neutropenic patients with severe idiopathic medullary aplasia (neutrophil 
count less than 500/mm3) (Grade 2+, weak agreement)
III. Acute respiratory failure management
RIII‑1—Acute respiratory failure should be considered as a therapeutic emergency in critically ill patients with neutropenia (Grade 1+, strong agree‑
ment)
RIII‑2—Etiological diagnosis of ARF should be considered as a primary objective in this setting (Grade 1+, strong agreement)
RIII‑3—The diagnostic workup should include systematic analysis of the underlying condition, severity and duration of neutropenia, underlying immu‑
nosuppression, preexisting treatment and prophylaxis, clinical course of ARF, and clinical and radiological features (Grade 1+, strong agreement)
RIII‑4—Invasive and non‑invasive diagnostic tests should probably be prescribed according to pretest probability rather than being performed system‑
atically. This should particularly be the case for bronchoscopy with bronchoalveolar lavage (Grade 2+, strong agreement)
RIII‑5—Pulmonary biopsies should probably be performed only on a case‑by‑case basis by a multidisciplinary team after careful assessment of both 
clinical suspicion and the risk‑to‑benefit ratio (Grade 2+, strong agreement)
IV. Organ failure and organ support
RIV‑1—Neutropenic enterocolitis (typhlitis) should probably be considered in critically ill neutropenic patients with fever and acute abdomen, particu‑
larly in cases of recent cancer chemotherapy known to be associated with a high rate of oral or gastrointestinal toxicity (Grade 2+, strong agreement)
RIV‑2—In adult patients, a complete diagnostic workup, including an abdominal CT scan with contrast media, should probably be performed (Grade 
2+, strong agreement). In the pediatric setting, abdominal ultrasonography should probably be performed as first‑line imaging (Grade 2+, strong 
agreement)
RIV‑3—First‑line colonoscopy should probably be avoided in patients with high suspicion of typhlitis (expert opinion, strong agreement)
RIV‑4—Management of typhlitis should include broad‑spectrum antibiotic therapy along with multidisciplinary management, including consultation of 
a general or abdominal surgeon (Grade 1+, strong agreement)
RIV‑5—Neutropenia and thrombocytopenia should not modify the timing of surgery in patients with suspicion of digestive tract perforation (Grade 1+, 
strong agreement)
RIV‑6—Neutropenia in itself should probably not modify ventilatory support in critically ill cancer patients (Grade 2−, strong agreement)
RIV‑7—Invasive mechanical ventilation should probably not be delayed only as a consequence of neutropenia, underlying malignancy, or immuno‑
compromised status (Grade 2−, weak agreement)
RIV‑8—An indication for renal replacement therapy should probably not be modified by neutropenia in itself (Grade 2−, strong agreement)
V. Antibacterial therapy and source control management
RV‑1—Combination therapy with aminoglycoside should probably be used as initial antibiotic therapy in neutropenic patients with severe sepsis or 
septic shock (expert opinion, weak agreement)
RV‑2—Glycopeptide antibiotic adjunctive agents (or other agents active against resistant aerobic gram‑positive cocci) should probably be considered 
for the following specific clinical indications
V‑2‑a—Suspected catheter‑related infection (Grade 2+, strong agreement)
V‑2‑b—Skin or soft tissue infection (Grade 2+, strong agreement)
V‑2‑c—Severe sepsis or septic shock (Grade 2+, weak agreement)
V‑2‑d—Use of antipseudomonal ‑lactam agent with insufficient anti‑gram‑positive activity (ceftazidime, for example) (Grade 2+, weak agreement)
V‑2‑e—Grade III or IV mucositis (Grade 2+, weak agreement)
V‑2‑f−Known colonization with methicillin‑resistant Staphylococcus aureus (Grade 2+, weak agreement)
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constant mortality in the absence of neutropenia recov-
ery [25].
In addition, early ICU admission should probably be 
considered in this subgroup of patients. Hence, delayed 
ICU admission ranging from hours to days has been 
independently associated with increased mortality [26–
30]. Although the studies in this field were at high risk of 
bias, this finding, along with the high rate of secondary 
ICU admission in patients initially considered “too well” 
to benefit from ICU treatment [31], prompted experts to 
recommend early ICU admission of these patients.
Prophylaxis and protective isolation
RII‑1 Protective isolation should probably be con-
sidered in patients with profound (neutrophil count 
less than 500/mm3) and prolonged (expected neutrope-
nia duration more than 7 days) neutropenia (Grade 2+, 
strong agreement).
RII‑2 Protective isolation should not be considered as a 
sterile isolation (Grade 1−, strong agreement).
RII‑3 Protective isolation should not delay ICU admis-
sion or limit patients’ clinical monitoring or access to 
patients’ rooms in cases of emergency (Grade 1−, strong 
agreement).
Most of the studies assessing the benefits of protec-
tive isolation were performed more than two decades 
ago, in ward patients, and are at a high risk of bias. In 
these studies, full protective isolation (including geo-
graphic isolation, technical isolation, high-efficiency air 
filtration, and digestive decontamination) proved to be 
efficient in patients with profound and prolonged neu-
tropenia with regard to the rate of infection [32, 33], 
severe infection [32–36], induction failure, or mor-
tality rate [32, 36, 37]. The benefit of protective isola-
tion seems to be correlated with neutropenia severity, 
although the impact of functional neutropenia has 
never been assessed, to the best of our knowledge [32]. 
Most of the studies performed with partial protective 
isolation, however, failed to demonstrate any benefit 
[34, 37, 38]. Besides full protective isolation, benefits 
of high-efficiency air filtration have been underlined in 
several studies performed before the validation of anti-
fungal prophylaxis protocols [39–41].
With regard to the available evidence, protective iso-
lation might be of interest in patients with profound 
(neutrophil count less than 500/mm3) and prolonged 
neutropenia (expected duration more than 7  days). Ide-
ally, this protective isolation includes the following:
1. High-efficiency air filtration [filtration of 99.7  % of 
particles greater than or equal to 0.3  µm; Interna-
tional Organization for Standardization (ISO) class 5 
or better]
2. Geographic isolation
3. Technical isolation, including a face mask and a cap
Other measures (including gloves or digestive decon-
tamination) were found to be of debatable interest.
The benefits of protective isolation in patients with 
expected neutropenia shorter than 7 days or in patients 
with neutrophil counts greater than 500/mm3 are 
uncertain.
Table 2 continued
RV‑3—If used empirically, glycopeptide antibiotics should probably be reconsidered and discontinued in the following situations
 After 72 h and if no resistant gram‑positive cocci have been identified (expert opinion, weak agreement)
 If infection is related to bacteria susceptible to a ‑lactam agent (expert opinion, strong agreement)
RV‑4—Antibiotic de‑escalation should probably be considered in the following situations
 When infection is related to susceptible organism (expert opinion, strong agreement)
 In patients without documented bacterial infection and with stable clinical condition (expert opinion, weak agreement)
RV‑5—Indwelling catheters should probably be removed immediately in neutropenic patients with septic shock and no identifiable clinical infection 
(Grade 2+, strong agreement)
VI. Hematological management
RVI‑1—Prophylactic use of G‑CSF should probably be initiated or resumed in critically ill patients with neutropenia or requiring cancer chemotherapy 
with expected medullary toxicity (Grade 2+, weak agreement)
RVI‑2—G‑CSF should probably be stopped when worsening of respiratory status during neutropenia recovery is suspected or before neutropenia 
recovery in patients at high risk of worsening of respiratory status during neutropenia recovery (preexisting respiratory failure or pulmonary infection) 
(Grade 2+, strong agreement)
RVI‑3—In euvolemic patients, transfusion of packed red blood cells should probably be performed according to a restrictive strategy in such a way as 
to maintain hemoglobin above a 7 g/dl threshold (Grade 2+, strong agreement)
RVI‑4—Granulocyte transfusion should probably not be performed as adjunct therapy in neutropenic critically ill patients with severe infection (Grade 
2−, strong agreement)
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Studies performed in other settings, however, suggest 
that isolation decreases the quality of care, limits access 
to a patient’s room, and increases the risk of severe and 
severe avoidable adverse events [42, 43]. With regard to 
the limited quality of studies validating protective isola-
tion in the ward, the lack of studies dedicated to critically 
ill cancer patients, and the high risk of decreased access 
to instable patients consecutive to protective isolation, 
the experts strongly believe that protective isolation 
should not delay ICU admission, limit patients’ clinical 
monitoring, or limit access to patients’ rooms in cases of 
emergency.
Additional studies are warranted to confirm preexisting 
studies and validate potential benefits in ward or specific 
settings such as critical care.
RII‑4 Antibacterial prophylaxis should probably not be 
performed in critically patients with neutropenia (Grade 
2−, strong agreement).
Several studies and a meta-analysis have validated the 
benefits of antibacterial prophylaxis in patients with pro-
found and prolonged neutropenia [44–46]. Quinolones 
with and without gram-positive bacterial activity and 
co-trimoxazole have been validated in this regard [46]. 
These studies and a meta-analysis underlined the ben-
efits in terms of the risk of fever and documented bacte-
rial infection, as well as mortality [46]. However, routine 
use of these strategies was associated with an increased 
rate of bacterial resistance [46–49]. These studies were 
performed in non-critically ill patients [46]. To the best 
of our knowledge, no study to date has validated such 
antibacterial prophylaxis strategies in ICU settings, and 
no data are available to assess ecological risk with regard 
to bacterial resistance. The risk-to-benefit ratio of such 
prophylactic strategies is therefore unknown. Although 
additional studies are warranted, experts believe that 
bacterial prophylaxis should probably not be used in this 
setting.
RII‑5 Anti-Aspergillus prophylaxis should probably be 
used in critically ill neutropenic patients with acute mye-
loid leukemia or myelodysplastic syndrome with both 
induction and consolidation therapy used when neutro-
penia is expected to be profound (neutrophil count less 
than 500/mm3) and with an expected duration of at least 
15 days (Grade 2+, weak agreement).
RII‑6 Anti-Aspergillus prophylaxis should probably be 
used in high-risk critically ill neutropenic patients (mye-
loablative conditioning regimens, older patients, trans-
plant in patients with active disease, umbilical/placental 
cord blood transplant) (Grade 2 + , weak agreement).
RII‑7 Anti-Aspergillus prophylaxis should probably be 
used in critically ill neutropenic patients with severe idio-
pathic medullary aplasia (neutrophil count less than 500/
mm3) (Grade 2+, weak agreement).
Acute respiratory failure in patients with fungal infec-
tion remains associated with a grim outcome [50]. 
Although specific data in critically ill patients are lack-
ing, the risk of aspergillosis is closely correlated with the 
severity and duration of neutropenia, with a significantly 
higher risk in patients with profound neutropenia during 
15 days or more, which may occur during the induction 
or intensive consolidation of acute myeloid leukemia/
myelodysplastic syndrome or during a myeloablative 
regimen of an allogeneic stem cell transplantation. In this 
setting, two large randomized controlled trials (RCTs) 
with low levels of bias have validated anti-Aspergillus 
prophylaxis using posaconazole [51, 52]. These studies 
demonstrated a decreased rate of fungal infection [51, 
52] as well as decreased overall [51] and fungal mortality 
[52]. Similarly, anti-aspergillosis has been recommended 
in patients with severe idiopathic medullary aplasia [53]. 
Although specific data in critically ill patients are lack-
ing, experts have selected to recommend the use of anti-
Aspergillus prophylaxis in these specific subgroups of 
patients should they require ICU admission. Although 
these specific situations require prophylaxis, several 
uncertainties remain in ICU patients among which bio-
availability deserves to be mentioned. Thus, optimal dos-
age, administration scheme, formulation remain to be 
assessed in this specific population of patients [54].
Other subgroups of critically ill patients with neu-
tropenia may require anti-Aspergillus prophylaxis on 
a case-by-case basis. In these subgroups, the help of an 
attending hematologist may be required.
Similarly, specific antiviral and Pneumocystis prophy-
laxis may be required according to underlying malig-
nancy and previous treatments. These prophylaxes 
should probably be used according to the usual indica-
tions even in critically ill patients.
Acute respiratory failure
RIII‑1 Acute respiratory failure should be considered 
as a therapeutic emergency in critically ill patients with 
neutropenia (Grade 1+, strong agreement).
RIII‑2 Etiological diagnosis of ARF should be consid-
ered as a primary objective in this setting (Grade 1+, 
strong agreement).
RIII‑3 The diagnostic workup should include sys-
tematic analysis of the underlying condition, severity 
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and duration of neutropenia, underlying immunosup-
pression, preexisting treatment and prophylaxis, clini-
cal course of ARF, and clinical and radiological features 
(Grade 1+, strong agreement).
Acute respiratory failure remains a frequent complica-
tion of immunocompromised and neutropenic patients 
[22, 55]. Early management is associated with decreased 
mortality and might help in increasing the safety of 
diagnostic procedures such as bronchoscopy [28, 55]. 
Although several infectious and non-infectious etiologies 
might be involved and might be intricate in these patients 
[55–63], a systematic diagnostic workup may lead to a 
high-probability diagnosis in 70–80  % of patients with 
ARF [55–63]. ARF of unknown origin is associated with 
a grim prognosis, suggesting diagnosis to be a major goal 
of management of these patients [56–58, 64].
Several studies validated a non-invasive and inva-
sive systematic diagnostic workup that may explain the 
increasing rate of high-probability diagnoses in this set-
ting [56–58, 64]. This strategy includes a systematic 
analysis of the underlying malignancy and mechanism 
of immunosuppression, received treatment and prophy-
laxis, clinical and radiological picture, and clinical course 
of the respiratory failure [58]. This analysis is the first 
step in allowing the assessment of pretest probability 
and organization of a diagnostic test strategy. This pre-
test probability is mandatory to allow the interpretation 
of subsequent invasive and non-invasive test results. The 
reader may find more specific information regarding 
diagnostic workup in this setting in previous review [56, 
65].
RIII‑4 Invasive and non-invasive diagnostic tests 
should probably be prescribed according to pretest prob-
ability rather than being performed systematically. This 
should particularly be the case for bronchoscopy with 
bronchoalveolar lavage (Grade 2+, strong agreement).
Bronchoscopy with bronchoalveolar lavage (BAL) 
remains diagnostic in up to two-thirds of ARF cases in 
immunocompromised patients and is associated with 
therapeutic changes in 30–50  % of patients [57, 60, 64, 
66–84]. In addition, rate of respiratory deterioration 
in the hours following BAL is substantial, one-third of 
patients without invasive mechanical ventilation expe-
riencing significant respiratory worsening [57, 64]. In 
one RCT, researchers compared diagnostic strategies in 
critically ill patients without invasive mechanical ven-
tilation. These strategies were an invasive strategy with 
systematic BAL and a non-invasive strategy including a 
first-line non-invasive test (Additional file  1) along with 
subsequent BAL in patients without a diagnosis or in 
those requiring mechanical ventilation [64]. In that study, 
the need for mechanical ventilation, patient mortal-
ity, and the rate of patients without a diagnosis after the 
diagnostic workup were similar to both strategies [64]. 
Although these results suggest that BAL was well toler-
ated, they also challenge the diagnostic benefits of first-
line BAL when compared with a non-invasive diagnostic 
workup. BAL remains mandatory in cases of failure to 
obtain a diagnosis non-invasively or if deemed neces-
sary to validate a clinical or radiological suspicion (e.g., 
infiltrative pulmonary disease, alveolar proteinosis). In 
the same line, pretest probability should be the primary 
trigger in drawing optimal diagnostic workup rather than 
patients’ condition (with vs. without MV for example) or 
associated conditions (thrombocytopenia for example). 
When required, the rate of clinical worsening following 
BAL in patients requiring mechanical ventilation remains 
limited [57, 85].
RIII‑5 Pulmonary biopsies should probably be per-
formed only on a case-by-case basis by a multidiscipli-
nary team after careful assessment of both clinical sus-
picion and the risk-to-benefit ratio (Grade 2+, strong 
agreement).
After a negative diagnostic workup and BAL are per-
formed, transbronchial biopsies might be helpful in 
selected patients. They can be performed only after the 
control of bleeding risk. The complication rate is high, 
however, with pneumothorax occurring in 4–20 % of the 
patients, which is higher in patients requiring mechanical 
ventilation [78, 86–88].
Transparietal needle biopsies guided by either com-
puted tomography or ultrasonography may be helpful in 
patients with nodular and peripheral lesions [89–93].
Lastly, open-lung or video-assisted thoracoscopic lung 
biopsies can be performed in neutropenic patients under 
mechanical ventilation [94–96]. The latter should prob-
ably be performed when other diagnostic strategies have 
been exhausted after failure to obtain a diagnosis. When 
performed, these biopsies should probably include both 
pathological and extensive microbiological examination. 
However, the diagnostic rate, particularly in cases of dif-
fuse lung disease, is limited.
With regard to the high rate of complications, these 
diagnostic strategies should be discussed by multidisci-
plinary staff, the risk-to-benefit ratio should be carefully 
assessed, and these biopsies should ideally be performed 
in high-volume centers.
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Organ failure and organ support
RIV‑1 Neutropenic enterocolitis (typhlitis) should 
probably be considered in critically ill neutropenic 
patients with fever and acute abdomen, particularly in 
cases of recent cancer chemotherapy known to be asso-
ciated with a high rate of oral or gastrointestinal toxicity 
(Grade 2+, strong agreement).
Typhlitis usually occurs after cancer chemotherapy asso-
ciated with a high rate of oral or gastrointestinal toxicity 
(high-dose cytarabine for example). Clinical manifes-
tations of typhlitis include fever, abdominal cramping, 
abdominal distention, occlusion, pain and/or tender-
ness, diarrhea, and intestinal bleeding; however, they are 
relatively non-specific. In addition, several conditions 
encountered in neutropenic patients and including pseu-
domembranous colitis, digestive graft-versus-host dis-
ease (GVHD), viral infections, or acute surgical abdomen 
may mimic typhlitis. Standardized diagnostic criteria 
have been proposed by Groschlüter et al. [97]. These cri-
teria include the presence of profound neutropenia (neu-
trophil count less than 100/mm3), bowel wall thickening 
greater than 4  mm in a computed tomographic (CT) 
examination of any segment of the bowl at least 30 mm 
length, and the exclusion of other diagnoses, such as 
Clostridium difficile-associated colitis, GVHD, or other 
abdominal syndromes.
RIV‑2 In adult patients, a complete diagnostic workup, 
including an abdominal CT scan with contrast media, 
should probably be performed (Grade 2+, strong agree-
ment). In the pediatric setting, abdominal ultrasonogra-
phy should probably be performed as first-line imaging 
(Grade 2+, strong agreement).
RIV‑3 First-line colonoscopy should probably be 
avoided in patients with high suspicion of typhlitis 
(expert opinion, strong agreement).
Systematic diagnostic workup should be performed in 
patients with abdominal symptom compatible with typh-
litis following chemotherapy associated with a high rate 
of oral or gastrointestinal toxicity. Systematic abdominal 
CT scans with contrast enhancement may help in diag-
nostic confirmation and allow a search for complications 
such as perforations. In the pediatric setting, CT scans 
may be used as a second-line examination in cases of sus-
pected perforation and if ultrasonography is inconclusive 
[98–100]. In this setting, the feasibility and reliability of 
ultrasonography in measuring bowel wall thickness has 
been validated, with typhlitis being likely when bowel 
wall thickness measured by ultrasonography is greater 
than 3 mm [100]. In addition, the radiation dose associ-
ated with CT in the pediatric setting is important [101], 
and the use of ultrasonography may help in avoiding 
sedation, which is frequently required for CT scans.
Along with abdominal imaging, the diagnostic workup 
should include blood and stool cultures along with a 
search for C. difficile toxin. Although colonoscopy or 
recto-sigmoidoscopy may be required as second-line 
diagnostic test, these examinations are associated with a 
high risk of perforation in patients with suspected typh-
litis [102].
RIV‑4 Management of typhlitis should include broad-
spectrum antibiotic therapy along with multidiscipli-
nary management, including consultation of a general or 
abdominal surgeon (Grade 1+, strong agreement).
RIV‑5 Neutropenia and thrombocytopenia should not 
modify the timing of surgery in patients with suspicion of 
digestive tract perforation (Grade 1+, strong agreement).
In cases of typhlitis, conservative management is pre-
ferred. This treatment includes symptomatic measures 
such as maintenance of fluid and electrolyte balance, 
antalgic treatment, and monitoring. A nasogastric tube 
may be required in cases of ileus, and parenteral nutri-
tion may be required in cases of severe typhlitis. Use of 
granulocyte colony-stimulating factor (G-CSF) remains 
of uncertain benefit, and its routine use cannot be 
recommended.
Use of broad-spectrum antibiotic therapy remains 
the rule and should be adapted to local microbiologi-
cal ecology and patients’ colonization [103]. Ideally, this 
treatment should be active on Enterococcus, Enterobac-
teriaceae, anaerobes, and Pseudomonas aeruginosa [2, 
103]. The systematic use of glycopeptide or metronida-
zole is of uncertain benefit but has been advocated by 
some authors [2, 103]. First-line empiric antifungal ther-
apy cannot be recommended, owing to the low incidence 
of invasive fungal infection (5  %) during typhlitis [104]. 
Nevertheless, lack of clinical improvement within 72  h 
should prompt antifungal therapy initiation [104, 105]. 
Antibiotics are usually stopped after neutropenia and 
clinical recovery.
Surgical management may be required and may 
be prompted by meeting the following objec-
tive criteria: uncontrolled bleeding despite transfu-
sion, suspicion of gastrointestinal perforation, and 
clinical worsening despite conservative management 
[106]. Sequential abdominal imaging may be required 
and may help in assessing changes in bowel wall thick-
ness. Ultrasonography may help in this regard [107–110], 
and decreases in bowel wall thickness on sequential 
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ultrasonography have been associated with clinical 
improvement [108]. In contrast, mortality remains high 
(60 vs. 4 %; P < 0.001) in patients with bowel wall thick-
ness greater than 10 mm [111]. Aggressive surgical man-
agement in these patients should probably be discussed 
on a case-by-case basis.
Although surgical management requires a multidisci-
plinary assessment, several factors need to be taken into 
account. (1) First, inadequately treated typhlitis carries a 
high risk of death [112]. (2) In the more severe patients 
with typhlitis, lack of surgical management was found to 
be a significant adverse prognostic factor [113]. (3) Data 
obtained in non-cancer patients with thrombocytopenia 
suggest that even high-risk hemorrhage surgical inter-
vention such as splenectomy carries a low risk of morbid-
ity or mortality [114]. Taken together, these data suggest 
that neutropenia or thrombocytopenia per se should not 
lead to delayed surgical intervention in critically ill neu-
tropenic patients suspected of digestive tract perforation.
RIV‑6 Neutropenia in itself should probably not mod-
ify ventilatory support in critically ill cancer patients 
(Grade 2−, strong agreement).
RIV‑7 Invasive mechanical ventilation should probably 
not be delayed only as a consequence of neutropenia, 
underlying malignancy, or immunocompromised status 
(Grade 2−, weak agreement).
The need for mechanical ventilation has been asso-
ciated with a nearly constant mortality rate in cohort 
studies performed two decades ago or more [23, 115]. In 
addition, earlier cohort studies and small RCTs suggested 
non-invasive mechanical ventilation to be associated with 
a decreased rate of invasive mechanical ventilation and 
mortality in critically ill cancer patients with ARF [72, 
116–118]. However, findings regarding the benefits of 
prophylactic non-invasive ventilation were inconsistent 
[119], and recent cohort studies pointed out decreased 
mortality in patients requiring invasive mechanical ven-
tilation [120–122]. A recent randomized trial failed to 
demonstrate any benefits of non-invasive ventilation 
when compared with oxygen therapy in immunocompro-
mised patients [123]. With regard to available evidence, 
systematic use of non-invasive ventilation in immuno-
compromised patients no longer seems justified.
It must be noted that no study was specifically focused 
on pediatric patients. Additional studies in this setting 
are therefore required.
RIV‑8 An indication for renal replacement therapy 
should probably not be modified by neutropenia in itself 
(Grade 2−, strong agreement).
Although the need for renal replacement therapy (RRT) 
remains associated with a poor outcome in critically 
ill cancer patients, several recent observational studies 
demonstrated an overall mortality close to that for the 
general ICU population [7, 124]. Except for specific indi-
cations such as tumor lysis syndrome, the indications for 
RRT are similar to those in the general ICU population.
Antibacterial therapy and source control 
management
RV‑1 Combination therapy with aminoglycoside 
should probably be used as initial antibiotic therapy in 
neutropenic patients with severe sepsis or septic shock 
(expert opinion, weak agreement).
A systematic review of the literature failed to identify evi-
dence with a low risk of bias in critically ill neutropenic 
patients. Neutropenic critically ill patients with fever 
or suspicion of sepsis should be considered at high risk 
of severe infection and receive an empirical antibiotic 
therapy including an antipseudomonal β-lactam agent 
with activity against gram-positive bacteria [2]. In these 
patients, systematic use of combination therapy with ami-
noglycosides remains speculative. In a systematic review 
focused on the general neutropenic patient population, 
Paul et al. [125] found no benefit of combination therapy 
in terms of mortality. In addition, combination therapy 
was associated with an increased rate of renal toxicity 
[125]. Little information was available with regard to the 
more severe cases, however. Two low-level evidence stud-
ies specifically demonstrated a potential benefit of amino-
glycosides in critically ill patients with neutropenia and 
severe sepsis and/or septic shock [126, 127]. Although 
experts therefore recommend using combination therapy 
in this specific subgroup, they also underline the need for 
studies producing high-grade evidence in this setting.
RV‑2 Glycopeptide antibiotic adjunctive agents (or 
other agents active against resistant aerobic gram-posi-
tive cocci) should probably be considered for the follow-
ing specific clinical indications:
V-2-a–Suspected catheter-related infection (Grade 2+, 
strong agreement).
V-2-b–Skin or soft tissue infection (Grade 2+, strong 
agreement).
V-2-c–Severe sepsis or septic shock (Grade 2+, weak 
agreement).
V-2-d–Use of antipseudomonal β-lactam agent with 
insufficient anti-gram-positive activity (ceftazidime, 
for example) (Grade 2+, weak agreement).
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V-2-e–Grade III or IV mucositis (Grade 2+, weak 
agreement).
V-2-f–Known colonization with methicillin-resistant 
Staphylococcus aureus (Grade 2+, weak agreement).
Studies dedicated to critically ill neutropenic patients 
in this setting are lacking. Systematic reviews performed 
in the general population of neutropenic patients suggest 
a lack of efficacy and potential toxicity of glycopeptide 
antibiotics when used systematically as an adjunct to an 
antipseudomonal β-lactam agent [128, 129]. Although 
systematic use of these molecules cannot be advocated, 
several areas of uncertainty remain, including potential 
benefits in patients with more severe illness or in specific 
subgroups. Combination therapy including glycopeptide 
antibiotics or other agents active against resistant aero-
bic gram-positive cocci should probably be considered 
in patients with more severe illness, patients at high 
risk of typhlitis (i.e., patients with severe mucositis), and 
patients at high risk of resistant gram-positive bacterial 
infection.
RV‑3 If used empirically, glycopeptide antibiotics 
should probably be reconsidered and discontinued in the 
following situations:
After 72 h and if no resistant gram-positive cocci have 
been identified (expert opinion, weak agreement).
If infection is related to bacteria susceptible to a 
β-lactam agent (expert opinion, strong agreement).
RV‑4 Antibiotic de-escalation should probably be con-
sidered in the following situations:
When infection is related to susceptible organism 
(expert opinion, strong agreement).
In patients without documented bacterial infection 
and with stable clinical condition (expert opinion, 
weak agreement).
Antibiotic de-escalation has been advocated in the gen-
eral population of neutropenic patients [2]. Nevertheless, 
high-grade evidence is lacking in the general population 
and in critically ill neutropenic patients. A single, pro-
spective, monocentric study found that de-escalation 
could be performed in 44  % of neutropenic critically ill 
patients with antibiotic therapy, this de-escalation being 
well tolerated in both the short and long term [130].
Microbiological cultures should be performed in criti-
cally ill neutropenic patients [64]. Bacterial identifica-
tion may help in de-escalating antibiotic therapy, limiting 
exposure to wide-spectrum therapy and therefore limit-
ing the risk of subsequent multidrug-resistant bacterial 
infection or colonization [130, 131]. Empirical use of 
anti-gram-positive antibiotic therapy should be asso-
ciated with a search for methicillin-resistant S. aureus 
colonization. The sensitivity of this screening approaches 
100  % [132]. Should the results of microbiological cul-
tures and colonization screening for resistant gram-
positive bacteria be negative, empirical therapy should 
probably be reconsidered and in most of the clinical sce-
narios discontinued. Among receiving antipseudomonal 
β-lactam agents [2], de-escalation in patients with sus-
ceptible organisms or stable clinical condition may be 
considered and seems safe [130]. Although the experts 
advocated de-escalation in above-mentioned situations, 
high-quality evidences are needed in this field.
RV‑5 Indwelling catheters should probably be removed 
immediately in neutropenic patients with septic shock 
and no identifiable clinical infection (Grade 2+, strong 
agreement).
Immediate indwelling catheter removal has been inde-
pendently associated with increased survival in critically 
ill neutropenic patients and patients with severe sepsis 
and/or septic shock [126, 133]. Although additional stud-
ies may be required, experts advocate a liberal removal 
strategy in this subgroup of patients with severe illness.
Hematological management
RVI‑1 Prophylactic use of G-CSF should probably be 
initiated or resumed in critically ill patients with neutro-
penia or requiring cancer chemotherapy with expected 
medullary toxicity (Grade 2+, weak agreement).
Prophylactic use of G-CSF in patients with hematologi-
cal malignancy or solid tumors has proven efficacy in 
decreasing the risk or duration of neutropenia and lim-
iting the risk of infectious disease [134–136]. In meta-
analyses performed in patients with non-Hodgkin’s 
lymphoma or solid tumors, use of G-CSF was associated 
with a decrease in both overall mortality and infection-
related mortality [135–137]. Little data on this topic in 
the ICU are available, suggesting limited efficacy in this 
setting [72, 138], and it was obtained from studies with 
low-level evidence. Thus, despite uncertainties and while 
additional studies are needed, it seems reasonable to rec-
ommend using prophylactic G-CSF when available or 
deemed necessary by an oncologist or hematologist.
Conversely, use of G-CSF in patients with already overt 
infections (curative G-CSF) was found to have a limited 
benefit in neutropenic patients [139, 140]. In addition, 
only limited data exist in the ICU, and this treatment 
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remains associated with potential side effects, including 
risk of worsening respiratory status. Experts were unable 
to recommend use of curative G-CSF, and this treat-
ment should be used only on a case-by-case basis with an 
attending oncologist or hematologist.
RVI‑2 G-CSF should probably be stopped when wors-
ening of respiratory status during neutropenia recovery 
is suspected or before neutropenia recovery in patients at 
high risk of worsening of respiratory status during neu-
tropenia recovery (preexisting respiratory failure or pul-
monary infection) (Grade 2+, strong agreement).
Worsening of respiratory status may occur during the 
3-day period surrounding neutropenia recovery [141]. 
Both clinical [142–145] and experimental [146, 147] 
studies suggest G-CSF to be associated with respiratory 
worsening in this setting. Although all of these reports 
are of low-level evidence, they suggest that, along with 
the remaining uncertainties regarding G-CSF benefits 
in ICU patients, G-CSF should be stopped in high-risk 
patients in the days preceding neutropenia recovery.
RVI‑3 In euvolemic patients, transfusion of packed 
red blood cells should probably be performed accord-
ing to a restrictive strategy in such a way as to maintain 
hemoglobin above a 7 g/dl threshold (Grade 2+, strong 
agreement).
No specific study has been performed in neutropenic 
critically ill patients. However, several observational 
studies suggest an independent association between 
transfusion of packed red blood cells and increased mor-
tality rate and risk of nosocomial infection. A recent 
meta-analysis including 18 randomized studies (7593 
patients) suggested a decrease in risk of nosocomial 
infection with a restrictive transfusion strategy [148]. In 
patients with euvolemic anemia and without acute coro-
nary syndrome, available high-grade evidence suggests a 
restrictive strategy with the aim of maintaining a hemo-
globin threshold between 7 and 9 g/dl to limit the need 
for transfusion without an increase in mortality or car-
diac events compared with a liberal strategy [149, 150]. 
Experts believe that these results should be applied to 
neutropenic patients.
RVI‑4 Granulocyte transfusion should probably not 
be performed as adjunct therapy in neutropenic criti-
cally ill patients with severe infection (Grade 2−, strong 
agreement).
A recent systematic review of the benefits of granulo-
cyte transfusion in neutropenic patients with infection was 
inconclusive with regard to the limited number of studies 
available and high heterogeneity [151]. In addition, patients 
included in most of the studies had profound and pro-
longed neutropenia. A recent RCT failed to demonstrate 
any benefit of granulocyte transfusion, although the study 
was clearly underpowered to detect such an effect [152]. 
While the experts acknowledge the lack of adequately pow-
ered studies and believe additional studies are required, 
they believe that the remaining doubts, along with potential 
deleterious effects of granulocyte transfusion, justify limit-
ing this therapeutic option to clinical research.
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